Employee costs before and after treatment initiation for bipolar disorder

American Journal of Managed Care

Volumn 13, Issue 4, 2007, Pages 179-186

  Brook, Richard A ^a   Kleinman, Nathan L ^b   Rajagopalan, Krithika ^c  

^a Retrospective Analysis   (United States)

^b Analysis and Research   (United States)

^c ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; CARBAMAZEPINE; LITHIUM CARBONATE; NEUROLEPTIC AGENT; TIAGABINE; VALPROATE SEMISODIUM; VALPROIC ACID; ZONISAMIDE;

ADULT; ARTICLE; BIPOLAR DISORDER; CONTROLLED STUDY; COST CONTROL; EMPLOYEE; FEMALE; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH CARE; PRIORITY JOURNAL;

ADULT; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; COSTS AND COST ANALYSIS; FEMALE; HEALTH BENEFIT PLANS, EMPLOYEE; HEALTH CARE COSTS; HUMANS; LINEAR MODELS; MALE; RETROSPECTIVE STUDIES; SICK LEAVE;

EID: 34247188437     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Wyatt RJ, Henter I. An economic evaluation of manic-depressive illness: 1991. Soc Psychiatry Psychiatr Epidemiol. 1995;30:213-219.
2. Gardner HH, Kleinman NL, Brook RA, Rajagopalan K, Brizee TA, Smeeding JE. The economic impact of bipolar disorder in an employed population from an employer perspective. J Clin Psychiatry. 2006;67:1209-1218.
3. Bryant-Comstock L, Stender M, Devercelli G. Health care utilization and costs among privately insured patients with bipolar I disorder. Bipolar Disord. 2002;4:398-405.
4. Dean C, Gadd EM. Home treatment for acute psychiatric illness. BMJ. 1990;301:1021-1023.
5. Peele PB, Xu Y, Kupfer DJ. Insurance expenditures on bipolar disorder: clinical and parity implications. Am J Psychiatry. 2003;160:1286-1290.
6. Simon GE, Unützer J. Health care utilization and costs among patients treated for bipolar disorder in an insured population. Psychiatr Serv. 1999;50:1303-1308.
7. Bauer MS, McBride L, Williford WO, et al; Cooperative Studies Program 430 Study Team. Collaborative care for bipolar disorder, part II: impact on clinical outcome, function, and costs. Psychiatr Serv. 2006;57:937-945.
8. Simon GE, Ludman EJ, Bauer MS, Unützer J, Operskalski B. Long-term effectiveness and cost of a systematic care program for bipolar disorder. Arch Gen Psychiatry. 2006;63:500-508.
9. Elixhauser A, Steiner C, Palmer L; US Agency for Healthcare Research and Quality. Clinical Classifications Software, 2004. February 6, 2004. Available through HCUP Methods Series (report 2004-01 Comorbidity Software Documentation) at: http://www.hcup-us.ahrq.gov/reports/methods.jsp. Accessed November 4, 2004.
10. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis. 1987;40:373-383.
11. Kleinman NL, Brook RA, Rajagopalan K, Gardner HH, Brizee TA, Smeeding JE. Lost time, absence costs, and reduced productivity output for employees with bipolar disorder. J Occup Environ Med. 2005;47:1117-1124.
12. American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry. 2002;159(suppl):1-50.
13. Gilbert DA, Altshuler KZ, Rago WV, et al. Texas Medication Algorithm Project: definitions, rationale, and methods to develop medication algorithms. J Clin Psychiatry. 1998;59:345-351.
14. Rush AJ. Toward an understanding of bipolar disorder and its origin. J Clin Psychiatry. 2003;64(suppl 6):4-8, 28.
15. Hirschfeld RM, Lewis L, Vomik LA. Perceptions and impact of bipolar disorder: how far have we really come? Results of the National Depressive and Manic-Depressive Association 2000 survey of individuals with bipolar disorder. J Clin Psychiatry. 2003;64:161-174.
16. Matza LS, Rajagopalan KS, Thompson CL, de Lissovoy G. Misdiagnosed patients with bipolar disorder: comorbidities, treatment patterns, and direct treatment costs. J Clin Psychiatry. 2005;66:1432-1440.
17. Hirschfeld RM. The Mood Disorder Questionnaire: a simple, patient-rated screening instrument for bipolar disorder. Prim Care Companion J Clin Psychiatry. 2002;4:9-11.
18. Suppes T, Dennehy E, Hirschfeld RM, et al; Texas Consensus Conference Panel on Medication Treatment of Bipolar Disorder. The Texas Implementation of Medication Algorithms: update to the algorithms for treatment of bipolar I disorder. J Clin Psychiatry. 2005;66:870-886.
19. Keck PE Jr, Marcus R, Tourkodimitris S, et al; Aripiprazole Study Group. A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am J Psychiatry. 2003;160:1651-1658.
20. Olie JP, Levy E. Manic episodes: the direct cost of a three-month period following hospitalization. Eur Psychiatry. 2002;17:278-286.
21. Rajagopalan K, Kleinman NL, Brook RA, Gardner HH, Brizee TA, Smeeding JE. Costs of physical and mental comorbidities among employees: a comparison of those with and without bipolar disorder. Curr Med Res Opin. 2006;22:443-452.
22. Marken PA. Emerging treatments for bipolar disorder: safety and adverse effect profiles. Ann Pharmacother. 2006;40:276-285.
23. Narrow WE, Rae DS, Robins LN, Regier DA. Revised prevalence estimates of mental disorders in the United States: using a clinical significance criterion to reconcile 2 surveys' estimates. Arch Gen Psychiatry. 2002;59:115-123.